An Open-Label, Prospective Study Evaluating the Clinical and Immunological Effects of Higher Dose Granulocyte Colony–Stimulating Factor in ALS

Conclusions:
Higher-dose G-CSF was well tolerated in this cohort with no apparent effect on disease progression up to 1 year.

Source: Journal of Clinical Neuromuscular Disease - February 28, 2020 Category: Neurology Tags: Original Article Source Type: research